Pharmacopeia Inc

Pharmacopeia — Technical Presentation (May 2008)

26 slides from Pharmacopeia's technical presentation, May 16, 2008

  1. Slide 1: Need for Novel Antihypertensive Medications

    Need for Novel Need for Novel Antihypertensive Medications Antihypertensive Medications Joel M. Neutel, MD Principal Investigator, Phase 2a Study of PS433540 Member, Pharmacopeia Clinical Advisory Board

  2. Slide 2: Worldwide Blood Pressure Control in Treated Hypertensive Patients

    USA 53.1 Canada 41.0 Mexico 21.8 Turkey 19.8 Germany 33.6 Spain 38.8 Greece 49.5 England 29.2 Egypt 33.5 South Africa 47.6 Italy 37.5 Worldwide Worldwide Blood Blood Pressure Pressure Control Control in in Treated Treated Hypertensive Hypertensive Patients Patients Updated Updated from from Kearney

  3. Slide 3: Multifactorial Intensive Treatment in Diabetic Patients: the Steno-2 Study

    Multifactorial Multifactorial Intensive Intensive Treatment Treatment in in Diabetic Diabetic Patients Patients: the the Steno Steno-2 Study Study Gaede Gaede et al. N et al. N Engl Engl J Med Med 2003; 348: 383 2003; 348: 383-393 393 Macro Macro and and microvascular microvascular complications com

  4. Slide 4: Mean Decrease in Systolic BP

    Mean Decrease in Systolic BP Mean Decrease in Systolic BP -12 -10 -8 -6 -4 -2 0 Change in SBP (mmHg) Norvasc® Vasotec® HCTZ Avapro® Cardizem® Pool JL AJH 1997;10:117 Chrysant SG J Hum Hypertens 2003;17(6):425 Smith DHG AJH 2002;15:108S

  5. Slide 5: Efficacy: Up-titration of ARBs

    Efficacy: Up Efficacy: Up-titration of ARBs titration of ARBs -10.1 -8.3 -9.7 -9.8 -10.4 -10.2 -12 -10 -8 -6 -4 -2 0 Change in SBP (mm Hg) L50 L100 V80 V160 I150 I300 L = losartan V = valsartan I = irbesartan

  6. Slide 6: Rule of TENS

    “Rule of TENS Rule of TENS” 1 additional drug for every additional 10 mmHg 1 additional drug for every additional 10 mmHg reduction in blood pressure reduction in blood pressure A 20 B 20 A 20 Baseline Monotherapy - 10 - 20 A 20 C 20 B 20 mmHg

  7. Slide 7: Combination Therapy Often Required to Reach JNC Goals

    Chobanian AV et al. Hypertension. 2003;42:1206-1252. Chart adapted: Bakris GL et al. Am J Kidney Dis. 2000;36:646-661. ALLHAT. JAMA. 2002;288:2981-2997. Hansson L et al. Lancet. 1998;351:1755-1762. Combination Therapy Often Required to Reach JNC Goals Pepine CJ et al. JAMA. 2003;290:2805-2816. Wrigh

  8. Slide 8: Results of a Randomized, Double Blind, Placebo Controlled Study of PS433540

    Results of A Prospective, Randomized, Results of A Prospective, Randomized, Double Blind, Placebo Controlled Study to Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Evaluate the Safety and Efficacy of PS433540, a Dual Angiotensin (AT1) and PS433540, a Dual Angiotensin

  9. Slide 9: Study Design

    Study Design Study Design 24 HR ABPM 24 HR ABPM RANDOMIZATION Screening Placebo PS433540 200 mg PS433540 500 mg 4 weeks Single Blind Placebo 3-4 weeks Mean seated office SBP >150 - < 179 mmHg DBP < 110 mmHg Mean daytime SBP >140 - < 179 mmHg DBP < 110 mmHg Endpoints Endpoints Primary Primary – Mean

  10. Slide 10: Blood Pressure Measurement Definitions

    Blood Pressure Measurement Blood Pressure Measurement Definitions Definitions SBP = Systolic blood pressure (highest value) SBP = Systolic blood pressure (highest value) DBP = Diastolic blood pressure (lowest value) DBP = Diastolic blood pressure (lowest value) Mean 24 HR ABPM Mean 24 HR ABPM – aver

  11. Slide 11: Disposition

    Disposition Disposition (11) (11) Discontinued DB treatment Discontinued DB treatment 108 108 Available at database lock Available at database lock 93 93 Available for ABPM analyses Available for ABPM analyses (Efficacy Population) (Efficacy Population) (4) (4) ABPM data incomplete ABPM data incompl

  12. Slide 12: Reasons for Early Discontinuation

    Reasons for Early Discontinuation Reasons for Early Discontinuation PS433540 PS433540 8 1 1 3 3 Placebo Placebo 1 0 0 0 1 200 mg 200 mg 500 mg 500 mg 2 Total Total 2 Non Non-compliance compliance 0 Protocol violation Protocol violation 0 Adverse Event Adverse Event 0 BP uncontrolled BP uncontrolled

  13. Slide 13: Baseline Characteristics

    Baseline Characteristics Baseline Characteristics PS433540 PS433540 94 94 161 161 31 31 173 173 92 92 20 (80) 20 (80) 5 (20) 5 (20) 0 0 16 (64) 16 (64) 60 60 Placebo Placebo (N=25) (N=25) 91 91 160 160 31 31 171 171 90 90 29 (83) 29 (83) 3 (9) 3 (9) 2 (6) 2 (6) 1 (3) 1 (3) 20 (57) 20 (57) 59 59 200

  14. Slide 14: Change from Baseline: Mean 24HR ABPM

    -14.80 -10.1 -9.3 0.3 -12.20 -0.40 -20.0 -15.0 -10.0 -5.0 0.0 5.0 Mean . (mmHg) 95% CI DBP SBP * Change from Baseline Change from Baseline Mean 24HR ABPM Mean 24HR ABPM Placebo N=25 200 mg N=35 500 mg N=33 PS433540 * * P < 0.001 vs placebo * *

  15. Slide 15: Mean Hourly ABPM Systolic Blood Pressure

    Figure 1 Mean Hourly ABPM Systolic Blood Pressure (mm Hg) 8 a.m. 9 a.m. 10 a.m. 11 a.m. 12 p.m.1 p.m .2 p.m. 3 p.m. 4 p.m. 5 p.m . 6 p.m .7 p.m.8 p.m. 9 p.m.10 p.m . 11 p.m . 12 a.m .1 a.m . 2 a.m . 3 a.m . 4 a.m . 5 a.m .6 a. m .7 a.m . 110 120 130 140 150 160 170 200 mg V4 200 mg V7 500 mg V4 500

  16. Slide 16: Mean Hourly ABPM Diastolic Blood Pressure

    Figure 2 Mean Hourly ABPM Diastolic Blood Pressure (mm Hg) 8 a.m .9 a.m . 10 a.m. 1 1 a.m . 12 p .m. 1 p.m . 2 p.m. 3 p.m. 4 p.m . 5 p.m. 6 p.m . 7 p.m.8 p .m. 9 p.m . 10 p.m . 11 p.m . 12 a.m. 1 a.m .2 a.m . 3 a.m . 4 a.m .5 a.m . 6 a.m . 7 a.m . 62.5 65.0 67.5 70.0 72.5 75.0 77.5 80.0 82.5 85.0 87

  17. Slide 17: Change from Baseline: Mean Seated Office

    -9.8 -10.5 1.6 -17.3 -16.9 -4.2 -20.0 -15.0 -10.0 -5.0 0.0 5.0 Mean . (mmHg) 95% CI DBP SBP * Change from Baseline Change from Baseline Mean Seated Office Mean Seated Office Placebo N=24 200 mg N=35 500 mg N=32 PS433540 * * P < 0.001 vs placebo * *

  18. Slide 18: Change from Baseline: Mean Daytime ABPM

    -12.5 -10.7 1.0 -17.3 -13.7 1.9 -20.0 -15.0 -10.0 -5.0 0.0 5.0 Mean . (mmHg) 95% CI DBP SBP Change from Baseline Change from Baseline Mean Daytime ABPM Mean Daytime ABPM Placebo N=25 200 mg N=35 500 mg N=33 PS433540 ABPM 8:00 am ABPM 8:00 am – 4:00 pm 4:00 pm

  19. Slide 19: Change from Baseline: Mean Nighttime ABPM

    -6.8 -9.1 -2.7 -10.7 -14.3 -1.6 -20.0 -15.0 -10.0 -5.0 0.0 5.0 Mean . (mmHg) 95% CI DBP SBP Change from Baseline Change from Baseline Mean Nighttime ABPM Mean Nighttime ABPM Placebo N=25 200 mg N=35 500 mg N=33 PS433540 ABPM Midnight ABPM Midnight – 6:00 am 6:00 am

  20. Slide 20: Final 4 Hours of Dosing

    -4.7 -8.6 -8.2 -12.5 0.8 -1.2 -20.0 -15.0 -10.0 -5.0 0.0 5.0 Mean D (mmHg) 95% CI DBP SBP Change from Baseline Change from Baseline Final 4 Hours of Dosing Final 4 Hours of Dosing Placebo N=25 200 mg N=35 500 mg N=33 PS433540 ABPM Last 4 hours ABPM Last 4 hours

  21. Slide 21: Final 2 Hours of Dosing

    -4.1 -10.2 -5.5 -14.4 -2.1 -3 -20.0 -15.0 -10.0 -5.0 0.0 5.0 Mean D (mmHg) 95% CI DBP SBP Change from Baseline Change from Baseline Final 2 Hours of Dosing Final 2 Hours of Dosing Placebo N=25 200 mg N=35 500 mg N=33 PS433540 ABPM Last 2 hours ABPM Last 2 hours

  22. Slide 22: Adverse Events

    Adverse Events Adverse Events 1 (2.7) 1 (2.7) 2 (5.4) 2 (5.4) 1 (2.9) 1 (2.9) Nausea/gastritis Nausea/gastritis PS433540 PS433540 0 3 (8.8) 3 (8.8) 3 (8.8) 3 (8.8) 3 (8.8) 3 (8.8) 1 (2.9) 1 (2.9) 1 (2.9) 1 (2.9) 4 (11.8) 4 (11.8) 9 (26.5) 9 (26.5) Placebo Placebo (N=34) (N=34) n (%) n (%) 1 (2.7) 1

  23. Slide 23: Selected Laboratory Parameters: Liver Functions

    Selected Laboratory Parameters Selected Laboratory Parameters .YGT GT (U/L) (U/L) AST AST (U/L) (U/L) ALT ALT (U/L) (U/L) PS433540 PS433540 31.6 31.6 33.5 33.5 +3.9 +3.9 22.6 22.6 23.3 23.3 +1.9 +1.9 24.8 24.8 27.1 27.1 +3.0 +3.0 Placebo Placebo (N=34) (N=34) 35.7 35.7 36.2 36.2 +0.3 +0.3 23.8 23.8

  24. Slide 24: Selected Laboratory Parameters: Hematology

    Selected Laboratory Parameters Selected Laboratory Parameters Ht Ht (%) (%) Hb Hb (g/dL g/dL) PS433540 PS433540 43.9 43.9 44.7 44.7 +0.2 +0.2 14.4 14.4 14.7 14.7 +0.1 +0.1 Placebo Placebo (N=34) (N=34) 43.9 43.9 42.2 42.2 -1.8 1.8 14.3 14.3 13.9 13.9 -0.5 0.5 200 mg 200 mg (N=37) (N=37) 500 mg 500 m

  25. Slide 25: Safety Summary

    Safety Summary Safety Summary 2 Serious Adverse Events 2 Serious Adverse Events – syncopy/hyponatremia syncopy/hyponatremia (placebo) (placebo) – basal cell carcinoma (placebo lead basal cell carcinoma (placebo lead-in) in) AE profile similar across treatment groups AE profile similar across treatme

  26. Slide 26: Conclusions

    Conclusions Conclusions PS433540 effectively lowers systolic and PS433540 effectively lowers systolic and diastolic blood pressure in Stage I and II diastolic blood pressure in Stage I and II hypertensive patients hypertensive patients The magnitude of the treatment effect The magnitude of the treat

Pharmacopeia — Technical Presentation (May 2008) on 6ix